Extrait

To determine the antitumor efficacy of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks repeated every 6 weeks in patients having metastatic NSCLC who have previously failed a platinum-containing regimen and docetaxel (Taxotere)

Critère d'inclusion

• Histologically proven NSCLC (Stage IV or recurrent disease or locally advanced [Stage IIIB]) that is not amenable to surgery, radiation, or combined modality therapy with curative intent

Liens

• ictrp
• ictrp
• euctr
• euctr